Product Information

TRILEPTAL 150 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $5.7216 per EA under NDC 00078045605. Its NADAC has been published 387 times since Nov 28, 2013.

FDA first approved this application on Jan 14, 2000. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the oxcarbazepine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

TRILEPTAL 150 MG TABLET

oxcarbazepine
$5.7216per EA
High Outlier

Strength

150 mg/1

NDC

00078045605

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

1/7/2026

Active Ingredients

OXCARBAZEPINE

Approval Type

New Drug (NDA)

FDA Application

NDA021014

FDA Approved

1/14/2000

TE Code

AB

On Market Since

1/30/2000

Pharmacological Classes

Anti-epileptic Agent
Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for TRILEPTAL 150 MG TABLET has been published 387 times since Nov 28, 2013, and over the history we have for it it has risen 152.7%. The table below summarizes its recorded NADAC range and movement.

Current price$5.7216 per EA
All-time high$5.7216 (Aug 19, 2026)
All-time low$2.2645 (Nov 28, 2013)
52-week high$5.7216
52-week low$5.5550
Median price$4.3352
Average price$4.3587
Largest weekly change+19.0% (Oct 22, 2014)
Weeks tracked387
Tracking sinceNov 28, 2013

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

+2.6%

3Y

+24.5%

5Y

+24.5%

All

+152.7%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 98% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 98%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of TRILEPTAL 150 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for TRILEPTAL 150 MG TABLET, manufactured by Novartis Pharmaceuticals Corporation, is $5.7216 per EA (NDC 00078045605), effective Aug 19, 2026.

How has the price of TRILEPTAL 150 MG TABLET changed over time?

Over the history we have for it, the NADAC for TRILEPTAL 150 MG TABLET has risen 152.7%. It has been tracked across 387 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for TRILEPTAL 150 MG TABLET?

Since Nov 28, 2013, the NADAC for TRILEPTAL 150 MG TABLET has ranged from a low of $2.2645 (Nov 28, 2013) to a high of $5.7216 (Aug 19, 2026), with a median of $4.3352 per EA.

Are there cheaper alternatives to TRILEPTAL 150 MG TABLET?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OXCARBAZEPINE 150 MG TABLET, is $0.1037 per EA — about 98% below TRILEPTAL 150 MG TABLET.

Who manufactures TRILEPTAL 150 MG TABLET?

TRILEPTAL 150 MG TABLET (NDC 00078045605) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.